Prof Prof Dirk Schadendorf speaks with ecancer at the EADO 2018 congress in Barcelona about targeted therapy in NRAS mutant melanoma.
Prof Schadendorf explains that while BRAF mutations are favourable to treatment the NRAS mutation has proven harder to treat, with the NEMO study showing monotherapy not to be favourable.
He explains that for patients with a metastatic disease such as isolated systemic metastasis similar results or better can be achieved through surgery.
He details that there is promise from a study comparing nivolumab against chemotherapy DTIC with the use of nivolumab looking beneficial.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.